Jeong Eun Kwon¹, Yeong-Geun Lee¹, Tae Hee Kim¹, Gyoungok Gang², Gokce Altun², Farzana Mushtaq Ahmed³, Narayanaswamy Venkatappa⁴, Hyukjin Kwon⁵, Jihyeong Park⁵, Se Chan Kang^1,

This study evaluated the efficacy of UBPN01 (Salvia miltiorrhiza extract) for alleviating menopausal syndrome. This study was a randomized, double-blind, placebo-controlled clinical trial involving female subjects (40 – 60 years) with menopausal syndrome. Subjects were administered 600 mg/day UBPN01 or placebo, and efficacy endpoints were menopausal symptoms according to the total Kupperman Index (KI) score and individual categories. After 12 weeks, the total KI scores decreased and depression and vaginal dryness symptoms improved, especially in UBPN01 compared to placebo. Moreover, we observed no significant difference between the two groups in estradiol, follicle stimulating hormone, or luteinizing hormone. These results demonstrated that UBPN01 alleviates menopausal symptoms without notable side effects and improves quality of life, suggesting its efficacy as an alternative supplement for women ineligible for hormone therapy.

postmenopausal syndrome, clinical trial, Salvia miltiorrhiza, KI